Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. (1st August 2022)

• Record Type: Journal Article
• Authors: Massud, I; Krovi, A; Nishiura, K; Ruone, S; Li, L; Holder, A; Gary, J; Mills, P; Mitchell, J; Khalil, G; Pan, Y; Luecke, E; Gatto, G; Heneine, W; Garcίa-Lerma, J G; Johnson, L; van der Straten, A; Dobard, C
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 77:Number 11(2022)
• Page Start: 2964
• Page End: 2971
• Publication Date: 2022-08-01
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkac252
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Objectives: To advance the initiative of ending the global epidemic, long-lasting HIV protection is needed through sustained release of antiretroviral drugs for months to years. We investigated in macaques the safety and efficacy of biodegradable polycaprolactone implants releasing tenofovir alafenamide for HIV pre-exposure prophylaxis (PrEP). Methods: Implants were administered subcutaneously in the arm using a contraceptive trocar. Efficacy against vaginal simian-HIV (SHIV) infection was investigated in six pigtailed macaques that received two tenofovir alafenamide implants (0.35 mg/day), one in each arm, for a total release rate of tenofovir alafenamide at 0.7 mg/day. Macaques were exposed to SHIV twice weekly for 6 weeks. Statistical analyses were used to compare outcome with eight untreated controls. Histological assessments were performed on skin biopsies collected near implantation sites. Results: Median (range) tenofovir diphosphate level in PBMCs was 1519 (1068–1898) fmol/10 6 cells. All macaques with tenofovir alafenamide implants were protected against vaginal SHIV infection. In contrast, 7/8 controls were infected after a median of 4 SHIV exposures ( P = 0.0047). Histological assessment of tissues near tenofovir alafenamide implant sites showed inflammation and necrosis in 5/6 animals, which were not evident by visual inspection. Conclusions: We demonstrated complete protection against vaginal SHIV infection with two implants releasing a total of 0.7 mg of tenofovir alafenamide per day. We also identified tenofovir diphosphate concentrations in PBMCs associated with complete vaginal protection. Consistent with previous findings, we observed adverse local toxicity and necrosis near the tenofovir alafenamide implant site. Improved tenofovir alafenamide implants that are safe and maintain high efficacy have the potential to provide long-lasting protection against vaginal HIV infection.